Ambrx Biopharma Inc. (AMAM)
NYSE: AMAM
· Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM
Ambrx Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 53K | 1.12M | 24K | 2.25M | 2.25M | 1.3M | 1.61M | 1.16M | 1.16M | 2.57M | 2.57M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 53K | 1.12M | 24K | 2.25M | 2.25M | 1.3M | 1.61M | 1.16M | 1.16M | 2.57M | 2.57M |
Operating Income | -25.63M | -19.17M | -16.03M | -8.67M | -8.67M | -28.78M | -17.66M | -17.88M | -19.05M | -12.65M | -12.65M |
Interest Income | 2.87M | 1.64M | 741K | 555.5K | 555.5K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -22.84M | -17.52M | -15.23M | -13.14M | -13.14M | -28.71M | -21.06M | -19.53M | -19.53M | -12.66M | -12.66M |
Net Income | -22.99M | -17.83M | -15.3M | -13.25M | -13.25M | -28.84M | -22.65M | -21.19M | -19.53M | -14.51M | -14.51M |
Selling & General & Admin | 9.41M | 5.9M | 7.32M | 6.27M | 6.27M | 4.82M | 5.35M | 4.65M | 4.65M | 4.49M | 4.49M |
Research & Development | 16.27M | 14.39M | 9.75M | 10.27M | 10.27M | 18.06M | 14.7M | 16.11M | 16.11M | 11.04M | 11.04M |
Other Expenses | 59K | 10K | -1.01M | 42.93M | -126K | -144K | -784K | n/a | n/a | n/a | n/a |
Operating Expenses | 25.68M | 20.29M | 16.06M | -15.94M | -15.94M | 22.89M | 19.27M | -20.7M | -20.7M | -15.22M | -15.22M |
Interest Expense | n/a | 211K | 190K | 4.47M | 4.47M | 4.54M | n/a | 1.66M | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | 1.25M | 681.5K | 681.5K | n/a | 958K | 348K | 348K | 369.5K | 369.5K |
Cost & Expenses | 25.68M | 20.29M | -15.99M | -15.94M | -15.94M | 22.89M | -21.72M | -20.7M | -20.7M | -15.22M | -15.22M |
Income Tax Expense | 148K | 305K | 73K | 110.5K | 110.5K | 129K | 1.59M | 1.66M | n/a | 500.00 | 500.00 |
Shares Outstanding (Basic) | 62.25M | 55.9M | 45M | 38.62M | 38.62M | 38.6M | 38.59M | 20.45M | 38.37M | 2.54M | 2.54M |
Shares Outstanding (Diluted) | 62.25M | 55.9M | 45M | 38.62M | 38.62M | 38.6M | 38.59M | 20.45M | 38.37M | 2.54M | 2.54M |
EPS (Basic) | -0.37 | -0.32 | -0.34 | -0.34 | -0.34 | -0.75 | -0.59 | -1.04 | -0.51 | -5.72 | -5.72 |
EPS (Diluted) | -0.37 | -0.32 | -0.34 | -0.34 | -0.34 | -0.75 | -0.59 | -1.04 | -0.51 | -5.72 | -5.72 |
EBITDA | -25.11M | -20.23M | -15.97M | -8.79M | -8.79M | -23.63M | -17.1M | -18.46M | -18.46M | -12.16M | -12.16M |
EBIT | -25.63M | -17.31M | -15.04M | -11.3M | -8.67M | -16.98M | -21.06M | -17.88M | n/a | n/a | n/a |
Depreciation & Amortization | 381K | 368K | 66K | -124K | -124K | 5.15M | 558K | -586.5K | -586.5K | -490.5K | -490.5K |